CJC-1295 vs Ipamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Ipamorelin |
|---|---|---|
| Dose Range | 1 mg–2 mg | 100 mcg–300 mcg |
| Frequency | Less than daily | 2x daily |
| Cycle Length | 8–12 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. |
| Best For |
What They Have in Common
CJC-1295, Ipamorelin are both commonly used for:
Key Differences
Unique to Ipamorelin:
Which Has Stronger Evidence?
- Sleep Quality: Ipamorelin has stronger research support.
| Goal | CJC-1295 | Ipamorelin |
|---|---|---|
| Muscle Growth | high | high |
| Fat Loss | high | high |
| Sleep Quality | medium | high |
Key Studies
CJC-1295
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Drug testing and analysis, 2019
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Drug testing and analysis, 2019
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse, 2016
Ipamorelin
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
Animal reproduction science, 2024
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Physiology & behavior, 2024
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
International journal of colorectal disease, 2014
Ready to Learn More?
Looking for trusted sources?